CapsoVision, Inc. Form 8-K Summary
Business Context and Reporting Period
CapsoVision, Inc. (Nasdaq: CV) filed a Current Report on Form 8-K dated September 17, 2026. The filing announces the entry into a Material Definitive Agreement for a registered direct offering of common stock. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered direct offering of common stock.
- Shares Issued: 3,163,444 shares.
- Purchase Price: $5.69 per share (approximately 5% discount to the last reported sale price on September 16, 2026).
- Gross Proceeds: Approximately $18 million.
- Use of Proceeds: General corporate purposes, including sales and marketing, research and development, general and administrative matters, and working capital.
- Investors: All purchasers are existing stockholders. Major participants include Star One Global Capital Limited (approx. $5.0 million) and Eliyahou Harari (approx. $10.0 million).
Material Changes and Related Party Transactions
The filing discloses related person transactions as two of the purchasers, Star One Global Capital Limited (wholly owned by Ching-Hang Shen) and Eliyahou Harari, are related persons who each beneficially own more than 5% of the Company's outstanding Common Stock. The Company's audit committee reviewed and approved these transactions in accordance with the related person transaction policy. The offering was conducted without an underwriter or placement agent.
Outlook, Risks, and Management Commentary
The offering is expected to close on or about September 18, 2026, subject to customary closing conditions. The shares are being sold pursuant to a Registration Statement on Form S-3 declared effective on August 21, 2026. The filing does not provide specific forward-looking guidance on revenue or earnings, nor does it detail specific risks beyond standard closing conditions and customary representations.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $18 million gross proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Confirm the updated share count and dilution impact on existing shareholders post-closing.
- Monitor the Company's subsequent filings for the actual allocation of proceeds to R&D and sales initiatives.